Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 10/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273069 | 0.89 | NPC1 (0.47) | DRD2SLC18A3GRIN2BCARM1PRMT6 | |
| SCHEMBL13676333 | 0.89 | DRD2 (0.46) | DRD2SLC18A3GRIN2BCARM1PRMT6 | |
| SCHEMBL12272644 | 0.85 | DRD2 (0.41) | DRD2SLC18A3GRIN2BCARM1PRMT6 | |
| SCHEMBL18707815 | 0.82 | SLC18A3 (0.50) | DRD2SLC18A3KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL13141241 | 0.81 | TP53 (0.48) | DRD2SLC18A3TSHRSIGMAR1 | |
| SCHEMBL15528823 | 0.81 | SLC18A3 (0.49) | DRD2SLC18A3GRIN2BGRIN2DGRIN3B | |
| SCHEMBL3929472 | 0.81 | TP53 (0.51) | HRH3CYP1A2 | |
| SCHEMBL16879289 | 0.81 | ESR2 (0.55) | CYP2C9 | |
| SCHEMBL3469385 | 0.81 | BRD4 (0.41) | DRD2SLC18A3CYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL18714255 | 0.81 | DRD2 (0.57) | DRD2SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210290591-A1 | IMMUNOMODULATING UREA AZALIDES | ZOETIS SERVICES LLC | 2021-09-23 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | EMORY UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-7396943-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080085893-A1 | MATRIX METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-10 | — | — | US | disclosed |
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | RORA, RORB, RORC | DRD2 3876/4885SLC18A3 1357/4885GRIN2B 1057/4885 |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | DRD2 190/4885SLC18A3 1643/4885GRIN2B 443/4885 |
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | TACR1, TACR2, GPBAR1 | DRD2 1355/4885SLC18A3 974/4885GRIN2B 578/4885 |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | CBR3, CBR1, GRHPR | DRD2 1514/4885SLC18A3 2578/4885GRIN2B 2697/4885 |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | CYP2B6, CBR3, CYP2A6 | DRD2 313/4885SLC18A3 2093/4885GRIN2B 155/4885 |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | NPSR1, HRH4, OPRL1 | DRD2 169/4885SLC18A3 405/4885GRIN2B 67/4885 |
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | NLN, GAP43, PSEN2 | DRD2 3100/4885SLC18A3 9/4885GRIN2B 50/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | DRD2 4707/4885SLC18A3 2721/4885GRIN2B 2211/4885 |
| US-20080085893-A1 | MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP7, MMP9 | DRD2 3843/4885SLC18A3 2783/4885GRIN2B 1466/4885 |
| US-11771677-B2 | Immunomodulating urea azalides | ARG1, IL2, CD209 | DRD2 1167/4885SLC18A3 4725/4885GRIN2B 4158/4885 |
| US-20210290591-A1 | IMMUNOMODULATING UREA AZALIDES | ARG1, IL2, CD209 | DRD2 1167/4885SLC18A3 4725/4885GRIN2B 4158/4885 |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | GAP43, NLN, SNAP29 | DRD2 2554/4885SLC18A3 6/4885GRIN2B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.